"Rise in Weight-Loss Drug Use to Drive 1% GDP Growth in US, Predicts Goldman Sachs"

Goldman Sachs predicts that the widespread use of new weight-loss drugs in the US could increase the country's GDP by 1% in the coming years, as lower obesity-related complications are expected to improve workplace efficiency. The market for weight-loss drugs is projected to reach $100 billion annually by the end of the decade, with Novo Nordisk and Eli Lilly leading the race. The use of GLP-1 agonists, pursued by several companies, could potentially increase by 10 to 70 million consumers by 2028, leading to significant economic spillovers. This wave of healthcare innovation, combined with the use of weight-loss drugs, could raise the US GDP by 1.3% in the coming years.